Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchiveUBS Maintains Buy Rating on UDR

Live News EQUITY FLASH L impact Oct 14, 2026, 04:17 PM UTC

UBS Maintains Buy Rating on UDR

Valid market news retained in the public archive without immediate LiveCast distribution.

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

UDR

Related stories

JK Cement Q2 Profit Rises 8% to ₹173 Crore; Approves ₹130 Crore Paints Plant JK Cement reported September-quarter FY27 net profit of ₹173 crore, up 8% year on year, and revenue of ₹3,733.4 crore, up 24%. Its board approved a ₹130 crore paints plant in Telan M impact | EQUITY | Oct 24, 2026, 10:26 AM UTC Kotak Mahindra Bank Q2 Profit Rises 29%, Beats Estimates Kotak Mahindra Bank reported standalone net profit of 42.11… for the quarter, citing stronger loan demand and lower provisions for bad loans. M impact | EQUITY | Oct 24, 2026, 08:59 AM UTC Tech Mahindra Acquires Finastra Cash Management Suite The acquisition adds cash management, virtual accounts and liquidity management products to Tech Mahindra’s banking technology portfolio. M impact | EQUITY | Oct 24, 2026, 08:35 AM UTC KEC International Wins Rs 2,872 Crore Power Grid Orders The contracts support evacuation of 8.5 GW of renewable energy from Gujarat and take KEC’s FY27 year-to-date order intake beyond Rs 13,500 crore. M impact | EQUITY | Oct 24, 2026, 08:35 AM UTC Celcuity VIKTORIA-1 Subgroup Shows Longer PFS Than Alpelisib In PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer without liver metastases, median PFS was 21.5 months with the triplet regimen and 11.5 months with the doublet, v M impact | EQUITY | Oct 24, 2026, 08:18 AM UTC Compass Therapeutics Reports Positive Phase 2/3 BTC Results The company reported that tovecimig plus paclitaxel improved ORR to 18.0% versus 5.3% and median PFS to 4.7 versus 2.6 months in previously treated advanced biliary tract cancer (H M impact | EQUITY | Oct 24, 2026, 08:18 AM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Market Context
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.